Substitution of calcineurin inhibitors with sirolimus on left ventricular hypertrophy (LVH) of renal transplant recipients (RTR)
Completed
- Conditions
- Chronic allograft nephropathy in renal transplant recipientsleft ventricular hypertrophyInjury, Occupational Diseases, PoisoningFailure and rejection of transplanted organs and tissues
- Registration Number
- ISRCTN54216890
- Lead Sponsor
- San Martino University Hospital (Azienda Ospedaliera Universitaria San Martino) (Italy)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
1. Age 25-66 years, both males and females
2. Non diabetic RTR with biopsy-proven chronic allograft nephropathy
3. Patients who have received a single kidney in 2004
Exclusion Criteria
1. Diabetic RTR
2. Patients receiving kidney transplant from living donors
3. Patients receiving dual kidney allograft
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in left ventricular mass (LVMi) at 12 months
- Secondary Outcome Measures
Name Time Method Changes in serum creatinine as a measure of graft function at 12 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link sirolimus to left ventricular hypertrophy regression in renal transplant recipients?
How does substituting calcineurin inhibitors with sirolimus affect chronic allograft nephropathy progression in renal transplant recipients?
Are there specific biomarkers that predict response to sirolimus therapy in renal transplant patients with left ventricular hypertrophy?
What are the comparative safety profiles of sirolimus versus calcineurin inhibitors in renal transplant recipients?
What alternative immunosuppressive agents or combination therapies are being explored for left ventricular hypertrophy in renal transplant recipients?